• Blog

The biopharmaceutical industry’s Covid-influenced evolution

  • Joshua Harris

2020 was a transformative year for all businesses, but pharmaceutical companies in particular were challenged to innovate, collaborate and generate results directly connected to solving a public health crisis.

From the outset, it was clear that the industry's response to the Covid-19 pandemic would define pharmaceutical companies’ perceived efficiency, efficacy and ethics. Many biotech and pharmaceutical companies moved quickly toward a singular goal—perhaps signaling a broader shift in how the industry is thinking about the allocation of resources for new investments and development. The pandemic mobilized many companies into new and expanded research and development (R&D), with valuable results including multiple therapeutic solutions and breakthrough technologies for the future.


Complete the form to the right to read the full article

About the author

Joshua Harris is a Senior Vice President with responsibility for assessing and underwriting legal risk, focusing on patent and intellectual property matters. Prior to joining Burford, he was a litigator in Loeb & Loeb’s New York office, where his practice focused on pharmaceutical patent litigation and counseling, representing brand pharmaceutical companies dealing with issues including infringement, validity and enforceability of patents.

Read Joshua Harris's Profile
Joshua Harris

Joshua Harris

Senior Vice President